G1 Therapeutics initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Edward White started G1 Therapeutics with a Buy rating and $61 price target. The company’s trilaciclib could improve patient outcomes by maximizing the beneficial effects of chemotherapy, while minimizing myelosuppression and immunosuppression, White tells investors in a research note. He believes investors are missing the potential of trilaciclib, which he thinks become part of the standard of care for patients with CDK4/6-independent tumors, including small cell lung cancer and triple-negative breast cancer, that receive chemotherapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.